MetaVia Inc. Reports Improved Net Loss of $3.7 Million in Q1 2025

MetaVia Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $3.7 million, or $0.36 per share, a significant improvement from a net loss of $6.7 million, or $1.32 per share, in the same period last year. The company’s total operating expenses decreased by 43.5% to $3.9 million, down from $6.9 million in the prior year, primarily due to reduced research and development (R&D) and general administrative costs. R&D expenses fell to $2.3 million from $4.9 million, reflecting a decrease in activities related to the Phase 2a clinical trial for DA-1241, while general administrative expenses decreased to $1.6 million from $2.0 million.

In terms of financial position, MetaVia reported total assets of $12.1 million as of March 31, 2025, down from $16.3 million at the end of 2024. The company’s cash reserves also declined to $11.2 million from $16.0 million, while total liabilities decreased to $7.7 million from $8.3 million. The accumulated deficit increased to $139.5 million, highlighting the ongoing financial challenges faced by the company as it continues to invest heavily in clinical trials and product development.

Strategically, MetaVia is focused on advancing its two primary drug candidates, DA-1241 and DA-1726, which target metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company recently announced positive results from the Phase 1 trial of DA-1726 and is preparing for an end-of-Phase 2 meeting with the FDA regarding DA-1241. Additionally, MetaVia has entered into a license agreement with Dong-A ST Co., Ltd. for the development of these compounds, which has resulted in increased R&D expenses under a shared services agreement.

Operationally, MetaVia's workforce remains stable, with 19,564,214 shares of common stock outstanding as of May 14, 2025. The company continues to face significant risks, including the need for additional funding to support ongoing clinical trials and the potential for delays in product development due to market conditions. Looking ahead, MetaVia plans to fund its operations through equity offerings and collaborations, although it acknowledges the uncertainty surrounding its ability to secure financing on favorable terms. The company expects to continue incurring losses and negative cash flows in the near future as it advances its clinical programs.